Author/year | Age | Sex | Skin lesions | Sites of osteoarticular symptoms | PET/CT | Bone scintigraphy | ESR (mm/h) | CRP (mg/dL) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Time from onset | Sites of increased tracer uptake | SUVmax | Site of lesions on CT | Characteristics of lesions on CT | ||||||||
Kohlfuerst et al. 2003 [10] | 45 | M | PPP | Shoulder, tibia(R) | < 36 | Tibia, ankle* | NA | ACW | Hyperostosis | ACW, tibia | NA | NA |
Pichler et al. 2003 [11] | 48 | M | PPP, acne, seborrhiasis | ACW | > 48 | ACW | NA | ACW | Sclerosis | ACW | NA | NA |
Shibakuki et al. 2006 [12] | 57 | M | PPP, acne | ACW | ~ 240 | Normal | NA | CS | Bone defect, consolidation | ACW, CS, rib 6,7 | 15 | Normal |
Inoue et al. 2007 [13] | 74 | F | PPP | Back | 300 | CS, TS | NA | CS, TS, LS | Sclerosis, syndesmophyte, osteophyte formation | CS, TS, LS, SI | Elevated | Elevated |
Takeuchi et al. 2007 [14] | 50 | F | None | Neck, back, lumbus | 168 | ACW, CS, LS, SI, wrist | 1.6 | CS, LS, femoral neck | Osteosclerosis, osteolysis | ACW, CS, LS, SI, femoral neck | 87 | 2.5 |
Patel et al. 2009 [15] | 20 | F | PPP | Back | N/A | ACW, TS, SI | NA | NA | NA | SC, TS, SI | NA | NA |
Abuhid et al. 2010 [16] | 44 | F | PPP | ACW, SI | 36 | ACW, SI | 2.18 | ACW, SI | Sclerosis, irregularities | ACW, SI | NA | NA |
Canbaz et al. 2010 [17] | 18 | F | None | Diffuse, prominent in back | 9 | TS, LS, pelvis | NA | NA | NA | Spine, pelvic bones | 74 | NA |
Nakamura et al. 2010 [18] | 60 | F | None | Ankle(Bi), back | N/A | CS, LS, SI(L), shoulder(L) | 6.1 | NA | NA | NA | 99 | 6.379 |
Namkoong et al. 2015 [19] | 62 | M | None | ACW(R) | 3 | ACW | 4.0 | None | Normal | NA | NA | 13.45 |
Ikeda et al. 2015 [20] | 60 | F | Acne | ACW, hands(Bi) | N/A | ACW | NA | ACW | Hyperostosis | NA | NA | NA |
Dong et al. 2016 [21] | 60 | F | PPP | Back | 2 | TS, SS | NA | TS, SS | Osteolysis | TS, S1 | NA | NA |
Dong et al. 2016 [21] | 51 | F | None | Back | 7 | ACW, LS, SI | NA | ACW, SI | Osteosclerosis | ACW, spine, SI | NA | NA |